<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03862846</url>
  </required_header>
  <id_info>
    <org_study_id>REN001-101</org_study_id>
    <nct_id>NCT03862846</nct_id>
  </id_info>
  <brief_title>A Study of the Safety of REN001 in Patients With Primary Mitochondrial Myopathy</brief_title>
  <official_title>An Open-label Study to Evaluate the Safety and Tolerability of 12 Weeks Treatment With Oral REN001 in Patients With Primary Mitochondrial Myopathy (PMM), With an Optional Extension of Treatment</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Reneo Pharma Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Reneo Pharma Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess REN001 safety in subjects with primary mitochondrial
      myopathy
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    COVID-19 Pandemic sufficient data gathered to achieve the study objective
  </why_stopped>
  <start_date type="Actual">May 10, 2019</start_date>
  <completion_date type="Actual">April 23, 2020</completion_date>
  <primary_completion_date type="Actual">April 23, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Comparing Baseline to Week 12</time_frame>
    <description>Number of participants with Adverse Events as a measure of safety and tolerability</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adverse Events</measure>
    <time_frame>Continous to Week 48</time_frame>
    <description>Number of participants with Adverse Events as a measure of safety and tolerability</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">23</enrollment>
  <condition>Primary Mitochondrial Myopathy</condition>
  <arm_group>
    <arm_group_label>Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>REN001 Low Dose</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>REN001</intervention_name>
    <description>Once daily</description>
    <arm_group_label>Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subjects must give written, signed and dated informed consent

          -  Confirmed diagnosis of PMM according to the 2016 Rome Consensus recommendations

          -  Confirmed mitochondrial mutation with evidence of myopathy

          -  Able to remain on stable medication throughout the study

        Exclusion Criteria:

          -  Documented evidence of ongoing rhabdomyolysis

          -  Subjects with motor abnormalities other than related to mitochondrial disease

          -  Treatment with an investigational drug within 3 months prior to Day 1

          -  Hospitalised within 3 months prior to screening for any major medical condition

          -  Pregnant or nursing females
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Grainne Gorman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wellcome Centre for Mitochondrial Research</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Institute of Neurology, University College London</name>
      <address>
        <city>London</city>
        <zip>WC1N 3BG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wellcome Centre for Mitochondrial Research</name>
      <address>
        <city>Newcastle Upon Tyne</city>
        <zip>NE2 4HH</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>February 28, 2019</study_first_submitted>
  <study_first_submitted_qc>March 1, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 5, 2019</study_first_posted>
  <last_update_submitted>July 14, 2020</last_update_submitted>
  <last_update_submitted_qc>July 14, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Muscular Diseases</mesh_term>
    <mesh_term>Mitochondrial Myopathies</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

